BPC-157 CapsulesHealing & Recovery
Oral BPC-157 in 500 mcg capsules studied for gut and tissue repair.
- Status
- Research / not approved
- Developer
- P. Sikiric et al., University of Zagreb (orig. PL-14736, Pliva)
- Receptors / target
- No single receptor identified; implicated in nitric-oxide signaling, VEGFR2 and growth-hormone-receptor expression (same as injectable BPC-157)
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- gut / GI protectiontendon & ligament repairmuscle healingangiogenesiswound healing
Overview
BPC-157 Capsules are the oral (capsule) form of BPC-157, a synthetic 15-amino-acid peptide derived from a protein in gastric juice. The molecule is identical to the injectable version (sequence GEPPPGKPADDAGLV); only the route differs. BPC-157 is described in the literature as a "stable gastric pentadecapeptide," and much of its animal research — particularly on the gastrointestinal tract — used oral or intragastric dosing, which is the rationale for an oral format. It remains a research compound only: not an approved drug, and the evidence base is overwhelmingly preclinical.
Mechanism
BPC-157 does not act on a single identified receptor. Reported effects center on angiogenesis and cytoprotection — modulation of the nitric-oxide system, interaction with the VEGFR2 pathway, and up-regulation of the growth-hormone receptor in tendon fibroblasts in vitro. Taken orally, its documented stability in gastric juice is what makes the route mechanistically plausible, especially for local effects on the gut lining. These are mechanistic findings from cell and animal studies, not validated human pharmacology.
Clinical evidence
The published literature is almost entirely animal data (predominantly rats), including studies where BPC-157 was given orally/intragastrically and protected or healed the gastrointestinal lining (e.g., the ileoileal-anastomosis and inflammatory-bowel-disease models). The only human-trial history belongs to a related pharmaceutical formulation (PL-14736) studied early-phase for inflammatory bowel disease; there are no robust published human trials of the research-grade oral peptide sold today, and oral systemic absorption in humans is unproven. Treat human-benefit claims as unproven.
Safety profile
Animal studies report a wide safety margin with no lethal dose reached and few adverse effects, and the peptide is notably stable in gastric juice. However, human safety is not established — long-term effects, immunogenicity and effects in disease states are unstudied, and the US FDA has flagged BPC-157 as lacking the safety data required for pharmacy compounding. It is prohibited in sport (research/anti-doping concern). Research use only; not for human consumption — nothing here is medical or dosing advice.
- Weeks 1–4
No controlled human data exists. Anecdotal oral protocols describe gradual gut/soft-tissue symptom relief over weeks; oral systemic absorption in humans is unproven.
- Weeks 6–8
Self-reported plateau in typical anecdotal use; the human time-course is uncharacterized.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- No well-characterized human side effects (no controlled human trials)
- Animal studies report no significant toxicity at researched doses
- Oral bioavailability / systemic absorption in humans is unproven
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human contraindication data exist for BPC-157 in any form; the cautions below are theoretical and grounded in preclinical biology, not human findings.
- As a pro-angiogenic agent, BPC-157 carries a theoretical caution with active malignancy (new blood-vessel formation could in principle support tumor growth); this concern is animal-derived and has not been demonstrated in humans.
- Not for human consumption; research use only. People who are pregnant, breastfeeding, or managing any medical condition have no safety data to rely on.
- NSAIDs (preclinical/animal only)Rodent studies report BPC-157 counteracting NSAID-induced gut and organ damage; this is an animal finding, not a documented human drug interaction
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs BPC-157
Same molecule in injectable form; the injectable has the larger (still preclinical) evidence base
- vs KPV Capsules
Another oral research peptide often discussed for gut/anti-inflammatory support
FAQ
Is oral BPC-157 (capsules) FDA-approved?
No. BPC-157 in any form is not approved by the FDA, and the agency has flagged it as lacking the safety data required for pharmacy compounding. Capsules are sold research-use-only, not as a medicine.
Do BPC-157 capsules work as well as injections?
Unknown. BPC-157 is notably stable in gastric juice, which is the rationale for oral use, and much of the animal GI research used oral/intragastric dosing. But oral systemic absorption in humans is unproven, and there are no human trials comparing routes.
Is BPC-157 banned in sport?
Yes. BPC-157 is prohibited under anti-doping rules regardless of route, so oral capsules carry the same competition risk as injections.
How does BPC-157 work?
It does not act on a single identified receptor. Preclinical work points to cytoprotective and pro-angiogenic effects via the nitric-oxide system, the VEGFR2 pathway, and up-regulation of the growth-hormone receptor in tendon cells in vitro. These are cell and animal findings, not validated human pharmacology.
What is oral BPC-157 most researched for?
The largest preclinical signal is gastrointestinal: animal studies using oral or intragastric dosing reported protection and healing of the gut lining (including IBD and anastomosis models). Tendon, ligament and wound-healing effects come from injectable animal work. None of this is confirmed in humans.
How do BPC-157 capsules differ from injectable BPC-157?
It is the same molecule (sequence GEPPPGKPADDAGLV) in a different route. The injectable has the larger (still preclinical) evidence base for tendon and soft-tissue models, while the capsule leans on the peptide's gastric stability for local gut effects. Both are research-use-only with no human efficacy trials.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.